Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention.

Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N, Accardi G. · 2019

Read Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. by Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N, Accardi G. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6773825.txt.

Introduction

Aiello and co-authors review immunosenescence and how to oppose it strategically. With age, the immune system remodels and weakens. Older people face more infections, weaker vaccine responses, and more inflammatory disease. Two changes stand out: naive immune cells dwindle, while memory cells grow in share. Together with chronic low-grade inflammation, these are the hallmarks of immune aging.

Aging is plastic, so interventions may slow it. Diet, supplements, and immune-modulating treatments are the main levers. Dietary strategies chiefly target the chronic inflammation of aging. Drugs also show promise. Interleukin-7 can grow fresh naive T cells. Checkpoint inhibitors may restore tired T cell responses. The review clarifies the options for fighting immune decline.

Catalog record

CREATORAiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, Ligotti ME, Zareian N, Accardi G.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE116 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6773825

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention By Anna Aiello, Farzin Farzaneh, Giuseppina Candore, Calogero Caruso, Sergio Davinelli, Caterina Maria Gambino, Mattia Emanuela Ligotti, Nahid Zareian, Giulia Accardi Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2019.02247 ABSTRACT Abstract Aging is accompanied by remodeling of the immune system. With time, this leads to a decline in immune efficacy, resulting in increased vulnerability to infectious diseases, diminished responses to vaccination, and a susceptibility to age-related inflammatory diseases. An age-associated immune alteration, extensively reported in previous studies, is the reduction in the number of peripheral blood naïve cells, with a relative increase in the frequency of memory cells. These two alterations, together with inflamm-aging, are considered the hallmarks of immunosenescence. Because aging is a plastic process, it is influenced by both nutritional and pharmacological interventions. Therefore, the role of nutrition and of immunomodulation in immunosenescence is discussed, due to the multifactorial influence on these hallmarks. The close connection between nutrition, intake of bioactive nutrients and supplements, immune function, and inflammation demonstrate the key role of dietary strategies as regulators of immune response and inflammatory status, hence as possible modulators of the rate of immunosenescence. In addition, potential options for therapeutic intervention are clarified. In particular, the use of interleukin-7 as growth factor for naïve T cells, the function of checkpoint inhibitors in improving T cell responses during aging and, the potential of drugs that inhibit mitogen-activated protein kinases and their interaction with nutrient signaling pathways are discussed. Finally, it is suggested that the inclusion of appropriate combinations of toll-like receptor agonists may enhance the efficacy of vaccination in older adults. Keywords: aging, immunosenescence, immunomodulation, immunotherapy, nutrition INTRODUCTION People worldwide are living longer. In 2025, there will be about 1.2 billion people over the age of 60, increasing to 2 billion by 2050 (1). However, the increase in lifespan does not coincide with the increase in healthspan, i.e., the period of life free from serious chronic diseases and disability. In fact, the influence of aging on humans is responsible for physiological dysfunctions in the different tissues, organs, and systems, including the immune system (2, 3). The age-related involvement of immune system leads to a progressive reduction in the ability to trigger effective antibody and cellular responses against infections and vaccinations. This phenomenon, called immunosenescence, a term coined by Roy Walford, is multifactorial, and affects both natural and acquired immunity, although T lymphocytes are dramatically affected (4). In fact, aging process more extensively affects acquired immunity than innate immunity (3, 5). Several factors, such as genetics, nutrition, exercise, previous exposure to microorganisms, biological and cultural sex, and human cytomegalovirus (HCMV) status can influence immunosenescence (3, 6–11). Concerning sex, steroid hormones, linking to specific receptors, differentially modulate the immune system. In general, while estrogens increase the immune response, progesterone and androgens have immune suppressive actions. However, a few studies have analyzed the post-menopausal immune system (12). Therefore, it is unclear whether age-related changes in the immune system are different between men and women, although some data show that immunosenescence develops earlier in men than in women. This has been related to longer life expectancy of women (8, 13, 14). In addition, no evidence exists that males and females respond differently to therapeutic intervention against immunosenescence. Many studies have emphasized the importance of viruses, such as herpes viruses, responsible for both latent and chronic infections, in shaping T cell compartments during aging (15). In particular, HCMV seropositivity seems related to many functional T cell changes. HCMV status has a greater impact than age on the immune system, because the virus contributes to shape the immune profile and function during normal human aging (16–18). Understanding mechanisms of age-related disorders in immune regulation is important to identify more efficient strategies for immune rejuvenation and for effective induction of vaccination-mediated immunity in older individuals. Aging is a malleable process, affected by both nutritional and pharmacological interventions (19, 20). Therefore, immune system might also be prone to intervention. However, all possible therapies aimed at non-specifically “rejuvenating” the immune system might be counterproductive. In fact, the different parameters observed between young and older people could also be a product of the adaption vs. the exposome, i.e., all the stimuli that the immune system has undergone during life. Therefore, a targeted intervention for safe “rejuvenation” of the immune status in older people should be necessary (21). Within the past years, numerous studies of underlying mechanisms of age-related immune decline have laid the groundwork for the identification of targeted approaches (5, 22–24). We will discuss below the most relevant strategies currently being investigated. We will also considered the role of nutrition in immunosenescence and in its counteraction in the section on dietary strategies currently being investigated. Further, we will examine the available data on growth factors [i.e., on interleukin (IL)-7], on monoclonal antibodies (MoAbs) that affect immune checkpoints, and on drugs that inhibit mitogen-activated protein kinases (MAPK) and their interaction with nutrient signaling pathways. These treatments, representing a promising therapeutic approach, will be treated in the section on clinical approaches. In the section on the other approaches in development, we will suggest that the inclusion of appropriate combinations of toll-like receptor (TLRs) agonists might enhance the efficacy of vaccination-mediated immunity in older adults. Finally, at the end of conclusion, we will outline possible future approaches. SUMMARY OF IMMUNOSENESCENCE Innate Immunity The general picture of innate immunity in older people, which emerges from several studies, is that of the down-regulation of some functions and the up-regulation of others. We will discuss data on dendritic cells (DCs) due to their relevance for the immunotherapeutic approaches, including vaccination. For the other aspects of innate immunity in older individuals, see (3, 25, 26). Briefly, natural killer (NK) cell cytotoxicity is well-preserved in centenarians, and an increase in the actual number of NK cells is observed in healthy aging. Neutrophils show reduced function in bacteria phagocytosis and in the oxidative burst while macrophages show reduced chemotaxis and phagocytosis, and decreased cytokine production. DCs, the most potent antigen presenting cells (APCs), can be divided into three subsets according to the expression of various markers (CD123, CD1c, CD141), one subset of plasmacytoid DCs (pDCs) and two subsets of myeloid DCs (mDCs) (27). Both pDCs and mDCs express TLRs that recognize conserved pathogen-associated molecular patterns (PAMPs) on microbes, and are key regulators of antimicrobial host defense responses. The type of TLR-activated DC determines the cytokine pattern (28). There are discordant data on age-related changes in the frequency and absolute number of pDCs and mDCs. Regarding the ability to secrete cytokines upon stimulation, there are apparent inconsistencies in the available data for mDCs from older population. pDCs are instead characterized by a marked impairment of cytokine release in older people (27, 29). Recognition of microbial components by TLRs culminates in the secretion of type I interferons (IFNs) and cytokines that facilitate the coordination of innate to acquired immune responses. Peripheral blood mononuclear cells (PBMCs) isolated from older individuals (≥65 years) exhibited a delayed and altered response to stimulation with TLR agonists compared with cells obtained from young adults (≤ 40 years). This delayed response to agonists results in the reduced production of cytokines and

Read the complete text